ICD-10-CM Billable Code

M11.159

Familial chondrocalcinosis, unspecified hip

Clinical Classification Guidelines

Medical Intelligence & Overview

Familial chondrocalcinosis is a hereditary condition characterized by the abnormal deposition of calcium crystals in joint cartilage, leading to joint pain and stiffness. When affecting the hip joint, it can cause significant discomfort and mobility issues. The ICD-10 code M11.159 specifically refers to familial chondrocalcinosis that involves an unspecified hip joint, highlighting its familial and hereditary nature. This condition is part of a broader group known as calcium pyrophosphate dihydrate (CPPD) deposition disease. With a genetic component, familial chondrocalcinosis often develops gradually, primarily impacting older adults but can manifest earlier depending on genetic predisposition and environmental factors.

Causes & Symptoms

Clinical Causes: Inherited genetic mutations affecting cartilage metabolism that lead to abnormal calcium crystal deposits. Family history of similar joint conditions, suggesting a hereditary component. Environmental factors such as metabolic disorders, calcium or phosphate imbalances. Certain environmental or lifestyle factors that may accelerate cartilage degeneration or crystal deposition.

Key Symptoms: Joint pain, particularly during or after activity. Stiffness in the affected hip, especially after periods of rest. Swelling and tenderness around the hip joint. Reduced range of motion, making activities like walking or bending difficult. Recurring episodes of acute joint inflammation, which might feel like sudden severe pain and swelling. Possible crepitus or grinding sensations during joint movement.

Diagnostic & Treatment

Diagnosis Path: Diagnosing familial chondrocalcinosis involves a combination of clinical evaluation and diagnostic tests: - **Medical history and physical examination:** To assess symptoms and familial patterns. - **Imaging studies:** X-rays can reveal characteristic calcification within the cartilage of the affected joint. - **Joint fluid analysis:** Extracting fluid from the joint to identify calcium pyrophosphate crystals under polarized light microscopy. - **Blood tests:** To rule out other metabolic conditions that mimic or contribute to crystal deposition. A specialist, such as a rheumatologist, typically conducts these assessments to confirm the diagnosis and differentiate it from other joint diseases.

Treatment Protocols: Management of familial chondrocalcinosis focuses on alleviating symptoms and improving joint function: - **Medications:** Nonsteroidal anti-inflammatory drugs (NSAIDs) can help reduce pain and inflammation during flare-ups. - **Joint injections:** Corticosteroid injections may provide relief from inflammation. - **Physical therapy:** Exercises and therapies designed to strengthen muscles around the hip and improve joint flexibility. - **Lifestyle modifications:** Maintaining a healthy weight, engaging in low-impact activities, and avoiding joint overuse. - **Monitoring and regular check-ups:** To track disease progression and adapt treatment as needed. In some cases, surgical intervention may be required if joint damage is severe, though this is generally considered a last resort. It is essential for diagnosed individuals to work closely with healthcare providers to develop a personalized management plan and address any complications that may arise.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is M11.159 a billable ICD-10 code?
Yes, M11.159 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report M11.159?
Clinical documentation must specify the nature of Familial chondrocalcinosis, unspecified hip and any associated comorbidities for accurate reporting.

Cite this Clinical Reference